Mehrnaz Maleki Fischbach, MD
Rheumatology · Denver, CONPI 1487849642
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,828 of the $25,486 with a category attached, or 62.1%. Boehringer Ingelheim accounts for 71.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $13,910 and has fallen 95.3% since, to $650 in 2025.
Across 42 payments — averaging $606.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$18K
- Merck$6K
- Novartis$650
- Janssen Scientific Affairs, LLC$256
- Actelion Pharmaceuticals US, Inc.$124
- Lilly USA, LLC$113
- plus $284 from 5 others
Across 2 payments — averaging $23,215 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$46K
What the payments were for
- Consulting fees$6,60026%
- Speaking & faculty fees$15,82862%
- Travel & lodging$1,3655%
- Food & beverage$1,6947%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $18,318 |
| Merck | 9 | $5,741 |
| Novartis | 1 | $650 |
| Janssen Scientific Affairs, LLC | 2 | $256 |
| Actelion Pharmaceuticals US, Inc. | 1 | $124 |
| Lilly USA, LLC | 2 | $113 |
| AbbVie | 6 | $103 |
| Amgen | 3 | $82 |
| AstraZeneca | 2 | $38 |
| GSK | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,486 in reported general payments places this provider in the 85th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 14 | $218,839 |
| Humira(Cf) PenAdalimumab | 27 | $198,358 |
| Enbrel SureclickEtanercept | 25 | $180,056 |
| Orencia ClickjectAbatacept | 24 | $158,442 |
| RinvoqUpadacitinib | 18 | $155,600 |
| XeljanzTofacitinib Citrate | 28 | $141,618 |
| OtezlaApremilast | 22 | $101,350 |
| Humira(Cf)Adalimumab | 14 | $98,941 |
| OrenciaAbatacept | 14 | $92,401 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 12 | $91,643 |
| ForteoTeriparatide | 12 | $50,449 |
| Hydroxychloroquine Sulfate | 241 | $10,154 |
| Cevimeline Hcl | 21 | $4,260 |
| Colchicine | 36 | $3,233 |
| MethotrexateMethotrexate Sodium | 65 | $1,531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $103 | $254,54132 claims |
| AmgenOtezla | $82 | $101,35022 claims |
| Lilly USA, LLCForteo | $113 | $50,44912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 108 rheumatology providers in Colorado.
Other rheumatology in Denver
- Aryeh FischerDenver$114K
- Adam BerlinbergDenver$94K
- Rennie McCabeDenver$58K
- Barbara GoldsteinDenver$47K
- Christopher AntoliniDenver$34K
- Liudmila KastsianokDenver$22K
- David KormanDenver$20K
- Kathleen SrockDenver$19K
- Mary DemoruelleDenver$12K
- Leslie RoseDenver$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.